Saxon Interests Inc. Has $425,000 Position in Insmed Incorporated (NASDAQ:INSM)

Saxon Interests Inc. cut its stake in Insmed Incorporated (NASDAQ:INSM) by 6.9% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 6,163 shares of the biopharmaceutical company’s stock after selling 454 shares during the period. Saxon Interests Inc.’s holdings in Insmed were worth $425,000 at the end of the most recent quarter.

A number of other institutional investors have also recently modified their holdings of INSM. V Square Quantitative Management LLC acquired a new stake in shares of Insmed during the 3rd quarter worth approximately $30,000. GAMMA Investing LLC boosted its holdings in shares of Insmed by 71.3% in the 3rd quarter. GAMMA Investing LLC now owns 538 shares of the biopharmaceutical company’s stock valued at $39,000 after purchasing an additional 224 shares in the last quarter. Exchange Traded Concepts LLC boosted its holdings in shares of Insmed by 522.5% in the 3rd quarter. Exchange Traded Concepts LLC now owns 747 shares of the biopharmaceutical company’s stock valued at $55,000 after purchasing an additional 627 shares in the last quarter. Blue Trust Inc. increased its stake in shares of Insmed by 2,348.8% in the 3rd quarter. Blue Trust Inc. now owns 1,959 shares of the biopharmaceutical company’s stock valued at $131,000 after purchasing an additional 1,879 shares during the last quarter. Finally, JCIC Asset Management Inc. acquired a new position in shares of Insmed during the 3rd quarter worth $133,000.

Insmed Price Performance

Insmed stock opened at $72.42 on Friday. The firm has a market cap of $12.96 billion, a P/E ratio of -13.15 and a beta of 1.12. The stock’s 50 day moving average is $71.20 and its 200 day moving average is $72.47. The company has a debt-to-equity ratio of 2.03, a current ratio of 6.37 and a quick ratio of 5.99. Insmed Incorporated has a one year low of $21.92 and a one year high of $80.53.

Insmed (NASDAQ:INSM) last posted its quarterly earnings data on Thursday, October 31st. The biopharmaceutical company reported ($1.27) EPS for the quarter, missing analysts’ consensus estimates of ($1.19) by ($0.08). The firm had revenue of $93.40 million for the quarter, compared to the consensus estimate of $93.36 million. During the same quarter in the prior year, the company posted ($1.10) earnings per share. The business’s revenue was up 18.1% on a year-over-year basis. As a group, research analysts expect that Insmed Incorporated will post -5.44 EPS for the current year.

Analysts Set New Price Targets

INSM has been the topic of a number of recent analyst reports. HC Wainwright reiterated a “buy” rating and issued a $90.00 target price on shares of Insmed in a research report on Friday, November 1st. JPMorgan Chase & Co. lifted their price target on shares of Insmed from $74.00 to $83.00 and gave the company an “overweight” rating in a report on Friday, November 22nd. Truist Financial reissued a “buy” rating and issued a $105.00 price objective (up previously from $100.00) on shares of Insmed in a research note on Friday, November 1st. Finally, Bank of America upped their price target on shares of Insmed from $84.00 to $86.00 and gave the stock a “buy” rating in a report on Wednesday, October 9th. One analyst has rated the stock with a sell rating and sixteen have assigned a buy rating to the company. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $83.67.

Insiders Place Their Bets

In related news, COO Roger Adsett sold 2,444 shares of the stock in a transaction on Tuesday, January 7th. The shares were sold at an average price of $65.95, for a total transaction of $161,181.80. Following the transaction, the chief operating officer now directly owns 147,666 shares of the company’s stock, valued at $9,738,572.70. This represents a 1.63 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Martina M.D. Flammer sold 3,344 shares of Insmed stock in a transaction on Tuesday, January 7th. The shares were sold at an average price of $65.91, for a total transaction of $220,403.04. Following the completion of the sale, the insider now directly owns 102,766 shares of the company’s stock, valued at approximately $6,773,307.06. This trade represents a 3.15 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 104,740 shares of company stock worth $7,161,294. Company insiders own 4.60% of the company’s stock.

Insmed Profile

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed’s first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.